CAR Stock Recent News

Allogeneic, TSCM-rich dual CAR-T for the treatment of hematologic malignancies, including multiple myeloma Nomination triggers $15 million milestone payment to Poseida, extending cash runway into early 2026 Poseida Cell Therapy R&D Day to take place on Thursday, November 14 at 7 am PT / 10 am ET SAN DIEGO , Oct. 17, 2024 /PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage allogeneic cell therapy and genetic medicines company advancing differentiated non-viral treatments for patients with cancer, autoimmune, and rare diseases, today announced the nomination of a new development candidate under its collaboration with Roche. The nomination triggered a $15 million milestone payment from Roche to Poseida.

AMTB, CAR and BSET have been added to the Zacks Rank #24 (Strong Sell) List on October 15, 2024.

Maiden diamond drill program on CarLang B, C and E Zones intersected significant near surface mineralization CarLang C encountered highest grades to date on the CarLang Trend and covers an area approximately twice the size as the Company's CarLang A Deposit EV24-CAR06 intersected 241.70m grading 0.30% Ni, incl.7.5m grading 0.56% Ni and 1.5m at 0.96% Ni EV24-CAR08 intersected 234.00m grading 0.28% Ni, incl.37.50m grading 0.37% Ni, 13.50m grading 0.39% Ni and 19.50m at 0.37% Ni Mineralization intersected in EV24-CAR08 appears to be magmatic in origin with 1-5% disseminated sulphide observed in drill core 7 of 10 holes bottomed in targeted mineralization Drilling identifies 3 new zones of large-scale nickel mineralization over 7 kilometres of strike and remains open for expansion in multiple directions TORONTO, ON / ACCESSWIRE / October 8, 2024 / EV NICKEL INC. (TSXV:EVNI) ("EVNi" or the "Company") ") is pleased to announce exploration results for its recently completed diamond drill prog

Now dosing at dose expansion level of 450 million NXC-201 CAR+T cells. First cohort at 150 million CAR+T cells already successfully completed Each of these two doses have produced complete responses in prior clinical studies Lead site Memorial Sloan Kettering Cancer Center (MSKCC); 4 disclosed clinical sites so far NXC-201 is the only one-time CAR-T treatment option being studied for relapsed/refractory AL Amyloidosis in U.S. clinical trials AL Amyloidosis, a disorder of plasma cells that leads to progressive damage to the heart, kidney and liver, affects approximately 33,000 patients in the U.S. LOS ANGELES, CA, Oct. 02, 2024 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us”, “IMMX”) (Nasdaq: IMMX), a clinical-stage biopharmaceutical company developing cell therapies for AL Amyloidosis and select immune-mediated diseases, today announced advances in the NEXICART-2 clinical study of its CAR-T NXC-201 for relapsed/refractory AL Amyloidosi

Amendment will allow a second dose of CAR-T therapy to suitable patients SAN JOSE, Calif. , Sept. 30, 2024 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that it and partner Moffitt Cancer Center ("Moffitt") have submitted an amendment to the current protocol that governs its ongoing clinical trial utilizing a CAR-T therapy to treat ovarian cancer (NCT05316129).

SAN JOSE, Calif. , Sept. 18, 2024 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that it will present at the Ovarian Cancer Research Alliance's ("OCRA") International Gynecologic Cancer Conference taking place online September 25-27, 2024.

ST. PAUL, Minn. , Sept. 16, 2024 /PRNewswire/ -- ScaleReady and Bio-Techne Corporation (NASDAQ: TECH) today announced the launch of the G-Rex optimized ProPakTM GMP Cytokines, ideally tailored to high efficiency closed system cell and gene-modified cell therapy (CGT) manufacturing.

The most oversold stocks in the industrials sector presents an opportunity to buy into undervalued companies.

PARSIPPANY, N.J., Sept. 10, 2024 (GLOBE NEWSWIRE) -- Avis Budget Group, Inc. (NASDAQ: CAR) (the “Company”) announced today that its wholly-owned subsidiaries, Avis Budget Car Rental, LLC and Avis Budget Finance, Inc. (together, the “Issuers”), priced a private offering of $700 million aggregate principal amount of 8.250% senior notes due 2030 (the “Notes”), which represents a $200 million increase from the previously announced size of the offering. The Notes will have a maturity date of January 15, 2030. The closing of the offering of the Notes is expected to occur on September 13, 2024, subject to customary closing conditions. The Notes will be issued at par and guaranteed on a senior unsecured basis by the Company and certain of its U.S. subsidiaries.

PARSIPPANY, N.J., Sept. 10, 2024 (GLOBE NEWSWIRE) -- Avis Budget Group, Inc. (NASDAQ: CAR) (the “Company”) announced today that its wholly-owned subsidiaries, Avis Budget Car Rental, LLC and Avis Budget Finance, Inc. (together, the “Issuers”), intend, subject to market and other customary conditions, to offer $500 million aggregate principal amount of senior notes due 2030 (the “Notes”) in a private offering. The Notes will be guaranteed on a senior unsecured basis by Avis Budget Group, Inc. and certain of its U.S. subsidiaries.